Market Update: Eli Lilly & Company (NYSE:LLY) – Lilly Sets Dates and Conference Calls for 2016 Financial Guidance and Fourth-Quarter 2015 Financial Results

[PR Newswire] – INDIANAPOLIS, Dec. 15, 2015 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) will announce its financial guidance for 2016 on Tuesday, January 5, 2016 and, separately, will announce its fourth-quarter … Read more on this. Eli Lilly and Company (LLY) , currently valued at $90.57B, opened this morning at $85.18. Looking at the stock, its one day range is $85.02 to $85.98 and has traded between $68.31 and $92.85 over the past year. Priced at 24.68x this year’s forecasted earnings, LLY shares are relatively expensive compared to the industry’s -2.34x forward p/e ratio. And for passive income investors, the company pays shareholders $2.04 per share annually in dividends, yielding 2.45%. In a review of the consensus earnings estimate this quarter, 17 sell-side analysts are looking at $0.78 per share, which would be $0.03 better than the year-ago quarter and a $0.00 sequential decrease. Furthermore, our analysis shows the full-year EPS estimate to be $3.44, which would be a $0.66 better when compared to the last year’s annual results. The quarterly earnings estimate is predicated on a consensus revenue forecast of $5.33 Billion. If reported, that would be a 4.10% increase over the year-ago quarter. Recently, Berenberg Initiated LLY at Buy (Aug 27, 2015). Previously, Morgan Stanley downgraded LLY from Overweight to Equal-Weight. The average price target for LLY shares by the analysts covering the stock is $97.37, which is 14.31% above where the stock opened this morning. See more in (NYSE:LLY) Similar Articles: Market Update: Eli Lilly & Company (NYSE:LLY) – EXCLUSIVE-US insurers hold back Lilly’s death-defying diabetes drug Market Update (NYSE:LLY): Lilly to Participate in Morgan Stanley Global Healthcare Conference Market Update: Eli Lilly & Company (NYSE:LLY) – Lilly’s Humalog® 200 units/mL KwikPen® Now Available in U.S. Pharmacies